Analysts Set AstraZeneca PLC (LON:AZN) PT at GBX 7,542.80

AstraZeneca PLC (LON:AZN) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 7,542.80 ($97.40).

AZN has been the subject of a number of analyst reports. Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.81) target price on shares of AstraZeneca in a report on Monday, January 27th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th.

AstraZeneca Stock Performance

AstraZeneca stock opened at £116.08 ($149.90) on Friday. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The firm has a 50-day moving average of £115.32 and a 200-day moving average of £113.21. The firm has a market cap of £223.34 billion, a P/E ratio of 31.82, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1-year low of GBX 9,670 ($124.87) and a 1-year high of £133.88 ($172.88).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.